Head to head
Innospec vs Linde
Side-by-side on the measures that matter, with a plain-English read. Full detail: IOSP · LIN
IOSP
Innospec
97.42-1.15%
1-year price shape — +28% over the period
Quant Rating C · 68/100
vs
LIN
Linde
483.98-1.22%
1-year price shape — +4% over the period
Quant Rating D · 45/100
1-year performance, rebased to 100
Linde edges it on the scoreable measures. Linde earns the most per share.
| IOSP | LIN | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Specialty Chemicals |
| Last price | 97.42 | 483.98 |
| Change today | -1.15% | -1.22% |
| 1-year return | +27.7% | +4.3% |
| Market cap | $2.40B | $223.11B |
| 52-week range | 64.75 – 100.48 | 384.00 – 546.40 |
| Valuation | ||
| P/E (TTM) | 19.88 | 31.22 |
| P/E percentile, own 5-yr range | 41st | 8th |
| P/B | 1.79 | 5.71 |
| Dividend yield | 1.84% | 1.28% |
| Profitability & growth | ||
| EPS (TTM) | 4.67 | 14.61 |
| Net profit (TTM) | $115.03M | $6.73B |
| Revenue (TTM) | $1.84B | $35.45B |
| Revenue growth (YoY) | +11.8% | +9.3% |
| Gross margin | 27.5% | 48.3% |
| Operating margin | 8.1% | 27.1% |
| Net margin | 6.6% | 20.4% |
| Free cash flow (TTM) | $49.30M | $4.98B |
| Ownership & sentiment | ||
| Institutional ownership | 101.4% | 88.0% |
| Insider activity (12mo) | 33 buy / 17 sell | 33 buy / 13 sell |
| Short interest (% of float) | 2.1% | 1.3% |
| Analyst consensus | 100% buy (1) | 87% buy / 13% hold (15) |
| Analyst price target | $110 (+13%) | $557 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | C (68) | D (45) |
| Company | ||
| Employees | 2,450 | 65,177 |
| Founded | 1938 | 2017 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.